Anggraini Cecilia, Nusanti Syntia, Tahapary Dicky Levenus, Khoe Levina Chandra
Residency Program in Ophthalmology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Acta Med Indones. 2024 Oct;56(4):461-468.
Graves' ophthalmopathy (GO) ocular abnormalities can persist even after treatment, negatively impacting patients' psychological and social health. The Indonesian Graves' Ophthalmopathy Quality of Life (GO-QoL) Questionnaire has not been validated, hence it cannot measure patient quality of life, which is crucial to GO treatment. We aimed to provide a reliable Indonesian GO-QoL Questionnaire and identify an association between patient quality of life and clinical activity and the severity of GO.
The process of questionnaire validation involves transcultural adaptation and a cross-sectional design. The content validity index (CVI) and Cronbach's alpha assessed validity and reliability, respectively.
The CVI was 1.00 for the Indonesian GO-QoL questionnaire. The Cronbach's alpha for the visual function subscale value was 0.971, the appearance subscale value was 0.993, and the total score was 0.986. The appearance subscale and total score of GO patients' quality of life had a significant association with clinical activity score (p<0.05) and disease severity (p<0.001).
The Indonesian version of the GO-QoL has good validity and reliability. Both the active clinical activity of GO and the severity of the disease decreased patients' appearance and general quality of life.
格雷夫斯眼病(GO)的眼部异常即使在治疗后仍可能持续存在,对患者的心理和社会健康产生负面影响。印度尼西亚格雷夫斯眼病生活质量(GO-QoL)问卷尚未经过验证,因此无法衡量患者的生活质量,而这对GO的治疗至关重要。我们旨在提供一份可靠的印度尼西亚GO-QoL问卷,并确定患者生活质量与GO临床活动及严重程度之间的关联。
问卷验证过程包括跨文化适应和横断面设计。内容效度指数(CVI)和克朗巴哈系数分别评估效度和信度。
印度尼西亚GO-QoL问卷的CVI为1.00。视觉功能子量表值的克朗巴哈系数为0.971,外观子量表值为0.993,总分值为0.986。GO患者生活质量的外观子量表和总分与临床活动评分(p<0.05)和疾病严重程度(p<0.001)有显著关联。
印度尼西亚版的GO-QoL具有良好的效度和信度。GO活跃的临床活动和疾病严重程度均会降低患者的外观和总体生活质量。